Brind.

A study evaluated gene therapy for Fabry disease patients involving ERT and Sangamo Therapeutics.

1 report, 1 independent Updated Jul 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A study evaluated gene therapy for Fabry disease patients involving ERT and Sangamo Therapeutics.

Who's involved

What this event is mainly about
ERTSangamo Therapeutics

Keep exploring

The entities involved

  • ERT

    company specializing in customizable medical devices to biopharmaceutical organizations

    Nothing else this week.

  • Sangamo Therapeutics

    American biotechnology company

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • Insider MonkeySangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy Sangamo Therapeutics Inc. (NASDAQ:SGMO) is one of the best penny stocks under $1 to buy now. On June 24, S